TOCAGEN INC (NASDAQ:TOCA) will announce its earnings results after the market closes on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.

TOCAGEN INC (NASDAQ:TOCA) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.04). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. On average, analysts expect TOCAGEN INC to post $-2.85 EPS for the current fiscal year and $-2.77 EPS for the next fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at

An institutional investor recently bought a new position in TOCAGEN INC stock. California State Teachers Retirement System bought a new stake in TOCAGEN INC (NASDAQ:TOCA) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 14,900 shares of the company’s stock, valued at approximately $179,000. California State Teachers Retirement System owned approximately 0.09% of TOCAGEN INC as of its most recent filing with the SEC. Institutional investors own 37.87% of the company’s stock.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of TOCAGEN INC from a “hold” rating to a “sell” rating in a research note on Wednesday, September 27th. Stifel Nicolaus restated a “buy” rating and issued a $24.00 target price on shares of TOCAGEN INC in a research note on Tuesday, July 25th.

TOCAGEN INC Company Profile

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Receive News & Ratings for TOCAGEN INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TOCAGEN INC and related companies with's FREE daily email newsletter.